RxDoctor Payments Data

Anthony Perna, MD

Internal Medicine · Buffalo, NYNPI 1568429330

Payments from drug & device makers

$1,339in general payments, 2019–2025

Across 32 payments — averaging $41.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$213
  • Dexcom, Inc.$167
  • AstraZeneca$145
  • Amarin Pharma, Inc.$137
  • Paratek Pharmaceuticals, Inc.$125
  • Phathom Pharmaceuticals, Inc.$125
  • plus $427 from 7 others

What the payments were for

  • Food & beverage$1,32799%
  • Education$121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,339 in reported general payments places this provider in the 75th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$32,138
Medicare patients
174
Services billed
327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin245$250,778
OzempicSemaglutide152$208,631
EliquisApixaban226$190,191
MounjaroTirzepatide100$120,302
TrulicityDulaglutide90$104,299
XareltoRivaroxaban57$66,837
JanuviaSitagliptin Phosphate31$36,852
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$23,527
SynthroidLevothyroxine Sodium260$17,953
InvokanaCanagliflozin20$16,804
Fluticasone-SalmeterolFluticasone Propion/Salmeterol70$16,585
Rosuvastatin Calcium841$16,194
Repatha SureclickEvolocumab17$15,915
Lantus SolostarInsulin Glargine,hum.Rec.Anlog98$15,132
Atorvastatin Calcium851$15,056

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$113$260,035257 claims
Novo NordiskOzempic$61$208,631152 claims
PfizerEliquis$123$190,191226 claims
MerckJanuvia, Lagevrio (Eua)$213$43,37344 claims
GSKTrelegy Ellipta, Breo Ellipta$38$34,55855 claims
AstraZenecaFarxiga, Symbicort$145$20,85137 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Buffalo

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →